arrow
K

Katherine P. Theall

Tulane University
H指数:46
被引数:7,268

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adverse childhood experiences and use of corporal punishment among women in low-resource settings: a convergent mixed methods study with mothers of children under five in the Dominican Republic

低资源环境女性中的不良童年经历与体罚使用:一项在多米尼加共和国5岁以下儿童母亲中进行的趋同性混合方法研究

2025-12-030
OAAI
COVID-19 vaccination likelihood among federally qualified health center patients: Lessons learned for future health crises (vol 366, pg 321, 2023)

联邦资格健康中心患者的新冠疫苗接种可能性:对未来健康危机的启示(卷 366,页 321,2023)

2025-09-010
PRE
Clinical trial participation among underserved communities: Insights from the Louisiana Community Engagement Alliance (vol 366, pg 254, 2023)

临床试验参与情况在服务不足的社区:来自路易斯安那社区参与联盟(vol 366, pg 254, 2023)的见解

2025-09-010
OAAI
Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase Ib/II study

Elacestrant与abemaciclib联合治疗雌激素受体阳性(ER+)、人表皮生长因子受体2阴性(HER2-)乳腺癌脑转移(mets)患者的初步数据:来自ELECTRA研究(一项开放标签、多中心、 Ib/II期研究)的初步数据

2024-09-010
PRE
Elacestrant combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Preliminary data from ELEVATE, a phase Ib/II, open-label, umbrella study

Elacestrant联合疗法在雌激素受体阳性(ER+)、人表皮生长因子受体2阴性(HER2-)局部晚期或转移性乳腺癌(mBC)患者(pts)中的研究:来自ELEVATE试验(一项开放标签的Ib/II期伞式研究)的初步数据

2024-09-013
PRE